<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01224041</url>
  </required_header>
  <id_info>
    <org_study_id>PRGRA-09-02-KOR</org_study_id>
    <nct_id>NCT01224041</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Shown Unsuccessful Response to Methotrexate</brief_title>
  <official_title>Clinical Study to Evaluate the Efficacy of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against Methotrexate: Non-comparative, Single Arm, Multi-center, Phase 4 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Korea, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate efficacy of 6 months treatment of tacrolimus in active Rheumatoid
      Arthritis patients who showed unsuccessful response against methotrexate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ACR20 response rate compared to baseline</measure>
    <time_frame>Baseline and up to 6 months</time_frame>
    <description>ACR20: 20% Improvement in American College of Rheumatology Core Set</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR50 response rate compared to baseline</measure>
    <time_frame>Baseline and up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR70 response rate compared to baseline</measure>
    <time_frame>Baseline and up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in 100mm pain VAS (Visual Analogue Scale)</measure>
    <time_frame>Baseline and up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in DAS 28 response rate</measure>
    <time_frame>Baseline and up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the incidence of adverse event and abnormalities in clinical laboratory test</measure>
    <time_frame>For 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Tacrolimus group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>oral</description>
    <arm_group_label>Tacrolimus group</arm_group_label>
    <other_name>Prograf</other_name>
    <other_name>FK506</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with more than 6 months history of rheumatoid arthritis according to ACR
             criteria

          -  Patients who have been treated unsuccessfully to more than single DMARDs including
             methotrexate at the discretion of investigator

          -  ESR ≥ 30 mm/h or CRP ≥ 1.0 mg/dL (ESR: Erythrocyte Sedimentation Rate, CRP: C-Reactive
             Protein)

          -  Patients are required to have at least 3 of 66 joints assessed as swollen

          -  Patients are required to have at least 6 of 68 joints assessed as painful with
             pressure

        Exclusion Criteria:

          -  Pregnant or breast-feeding patients. Patients who plan to bear children or breast-feed
             during the study and within 6 month after completion of study

          -  Previous experience of tacrolimus (ointment excluded)

          -  Renal impairment or serum creatinine &gt; 1.4 mg/dL

          -  Liver function failure as follows: viral hepatitis, non-viral hepatitis, cirrhosis,
             SGOT/SGPT &gt; 2x upper limit normal

          -  Patients with history of pancreatitis, glucose intolerance or complication or who
             indicates any of the following criteria:Blood glucose level &gt;110mg/dl before the meal
             and &gt;200mg/dl after the meal HbA1c &gt; 6.4%

          -  Cardiac disease(ischemic heart disease, treatment-requiring arrhythmia, heart
             failure)or complications

          -  Other investigational drug within last 30 days

          -  Patients who have been treated with infliximab, adalimumab, or leflunomide within 8
             weeks of start of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jinju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=PRGRA-09-02-KOR</url>
    <description>Link to results on Astellas Clinical Study Results Web site</description>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2010</study_first_submitted>
  <study_first_submitted_qc>October 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2010</study_first_posted>
  <last_update_submitted>December 28, 2015</last_update_submitted>
  <last_update_submitted_qc>December 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tacrolimus</keyword>
  <keyword>Prograf</keyword>
  <keyword>Calcinurin inhibitor</keyword>
  <keyword>Rheumatoid arthritis (RA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

